ALLMedicine™ Mycobacterium Avium Complex Center
Research & Reviews 923 results
https://doi.org/10.1007/s40261-021-01010-z 10.1093/cid/ciaa241 10.1093/infdis/jiaa354 10.1093/jac/dkn059 10.1007/s40265-019-01095-z 10.1128/JCM.01612-13 10.1128/CMR.05030-11 10.1371/journal.pone.0108703 10.1128/AAC.00700-16 10.1164/rccm.201807-1318OC 10.1007/s13318-020-00669-7 10.1164/rccm.201604-0700OC 10.1513/AnnalsATS.202008-925OC 10.1164/rccm.201704-0792LE
Clinical Drug Investigation; Hoy SM
Mar 16th, 2021 - Amikacin liposome inhalation suspension (ALIS) [Arikayce® Liposomal (EU); Arikayce® (USA)], a liposomal suspension of the aminoglycoside amikacin (590 mg) for nebulization via the Lamira® Nebulizer System, is available as add-on therapy for treatm...
https://doi.org/10.1128/AAC.02611-20
Antimicrobial Agents and Chemotherapy; Kim DH, Kim SY et. al.
Mar 9th, 2021 - We evaluated the in vitro activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs aga...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938981
BMJ Case Reports; Fernandes AL, Ferro A et. al.
Mar 6th, 2021 - Non-tuberculous mycobacterial pulmonary disease may have different clinical manifestations. We report a case of a 64-year-old woman presenting with persistent respiratory complaints, fever and radiological findings. Initially, she was diagnosed wi...
https://doi.org/10.1128/AAC.02131-20
Antimicrobial Agents and Chemotherapy; Schulthess B, Schäfle D et. al.
Feb 23rd, 2021 - Recent outbreaks of cardiac surgery-associated Mycobacterium chimaera infections have highlighted the importance of species differentiation within the Mycobacterium avium complex and pointed to a lack of antibiotic susceptibility data for M. chima...
https://doi.org/10.1016/j.rmed.2021.106340
Respiratory Medicine; Han DW, Jo KW et. al.
Feb 22nd, 2021 - The temporal dynamics of cavity formation in patients with the noncavitary nodular bronchiectatic (NC-NB) form of Mycobacterium avium complex pulmonary disease (MAC-PD) have not yet been well described. We aimed to investigate the development of n...
Guidelines 1 results
https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/0
Office of AIDS Research Advisory Council
May 28th, 2018 - Opportunistic infections (OIs) were the first clinical manifestations that alerted clinicians to the occurrence of the acquired immunodeficiency syndrome (AIDS). Pneumocystis pneumonia (PCP), toxoplasma encephalitis, cytomegalovirus (CMV) retiniti.
Drugs 11 results see all →
Clinicaltrials.gov 961 results
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b
Mar 24th, 2021 - MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
https://doi.org/10.1007/s40261-021-01010-z 10.1093/cid/ciaa241 10.1093/infdis/jiaa354 10.1093/jac/dkn059 10.1007/s40265-019-01095-z 10.1128/JCM.01612-13 10.1128/CMR.05030-11 10.1371/journal.pone.0108703 10.1128/AAC.00700-16 10.1164/rccm.201807-1318OC 10.1007/s13318-020-00669-7 10.1164/rccm.201604-0700OC 10.1513/AnnalsATS.202008-925OC 10.1164/rccm.201704-0792LE
Clinical Drug Investigation; Hoy SM
Mar 16th, 2021 - Amikacin liposome inhalation suspension (ALIS) [Arikayce® Liposomal (EU); Arikayce® (USA)], a liposomal suspension of the aminoglycoside amikacin (590 mg) for nebulization via the Lamira® Nebulizer System, is available as add-on therapy for treatm...
https://doi.org/10.1128/AAC.02611-20
Antimicrobial Agents and Chemotherapy; Kim DH, Kim SY et. al.
Mar 9th, 2021 - We evaluated the in vitro activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs aga...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938981
BMJ Case Reports; Fernandes AL, Ferro A et. al.
Mar 6th, 2021 - Non-tuberculous mycobacterial pulmonary disease may have different clinical manifestations. We report a case of a 64-year-old woman presenting with persistent respiratory complaints, fever and radiological findings. Initially, she was diagnosed wi...
https://doi.org/10.1128/AAC.02131-20
Antimicrobial Agents and Chemotherapy; Schulthess B, Schäfle D et. al.
Feb 23rd, 2021 - Recent outbreaks of cardiac surgery-associated Mycobacterium chimaera infections have highlighted the importance of species differentiation within the Mycobacterium avium complex and pointed to a lack of antibiotic susceptibility data for M. chima...
News 21 results
https://www.mdedge.com/dermatology/article/212703/infectious-diseases/papulonecrotic-tuberculid-secondary-mycobacterium?channel=44
Brittany Urso, MD, Corey Georgesen, MD et. al.
Nov 20th, 2019 - To the Editor: Papulonecrotic tuberculid (PNT) is a cutaneous hypersensitivity reaction to antigenic components of Mycobacterium species, most commonly Mycobacterium tuberculosis. According to a PubMed search of articles indexed for MEDLINE using.
https://www.mdedge.com/pulmonary-health-hub/article/176296/pulmonology/fda-approves-arikayce-mac-lung-diseases
Christopher Palmer
Oct 3rd, 2018 - The Food and Drug Administration has approved an amikacin liposome inhalation suspension (Arikayce) for the treatment of lung disease that has been caused by members of the Mycobacterium avium complex and is refractory to other treatments. In a ra.
https://www.staging.medscape.com/viewarticle/902764
Sep 30th, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...
https://www.medscape.com/viewarticle/902764
Sep 30th, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...
https://www.medpagetoday.com/pulmonology/generalpulmonary/75407
Sep 28th, 2018 - WASHINGTON -- The FDA approved Insmed's amikacin liposome inhalation suspension (Arikayce) for a limited population of patients with a certain type of non-tuberculosis mycobacterial lung infection, the agency said today. In what was described as t...